Kiwi (Act d 1) IgE Test · Blood

If you have reacted to kiwi or worry that you might, this test answers a sharper question than a standard kiwi allergy panel. It measures whether your immune system makes antibodies against the single most important protein in kiwifruit, called Act d 1 (actinidin). Knowing your answer helps separate a true, potentially severe kiwi allergy from milder cross-reactions tied to pollen or latex.

Standard whole-extract kiwi tests miss many true allergies, detecting only about 17% of challenge-proven cases in one study. This component test zeroes in on the specific molecule most strongly linked to systemic reactions, including anaphylaxis. It is the difference between a vague yes-or-no and a sharper picture of what your immune system is actually targeting.

What This Test Actually Measures

Act d 1 is the main allergen in green kiwifruit and makes up roughly half of the soluble protein in the fruit. It is a cysteine protease, meaning it is an enzyme that breaks down other proteins. This test detects IgE (immunoglobulin E), an antibody your immune system produces when it learns to recognize a substance as a threat. When IgE binds to Act d 1 in your blood, it confirms your immune system has built a specific response to this protein.

IgE antibodies are made by your immune system's B cells (a type of white blood cell). The presence of Act d 1 IgE in your blood is what is known as sensitization, meaning your immune system is primed to react to kiwi. Sensitization alone does not always mean you will have symptoms, but it is the biological foundation for an allergic reaction.

Why Act d 1 Matters More Than the Others

Kiwi contains at least 13 proteins that can trigger IgE responses, but they are not equally important. Act d 1 stands apart for two reasons. First, it is more often found in people who are mono-allergic to kiwi, meaning their allergy is to kiwi itself rather than a cross-reaction with pollen. Second, IgE to Act d 1 (often together with another component called Act d 3) is associated with the most severe reactions, including anaphylaxis.

The other major kiwi allergens tell a different story. Act d 8 is related to birch pollen protein, and Act d 9 is a profilin, both linked to pollen-related kiwi reactions that are usually milder and limited to the mouth. Act d 10 is a lipid transfer protein associated with a separate syndrome. Knowing which proteins your IgE targets reveals what kind of kiwi allergy you actually have.

Risk of Severe Reactions

In a large European study of 3,111 participants across multiple countries, sensitization to Act d 1 was an independent predictor of severe kiwi allergy, with roughly four times the odds of severe reactions compared to those without Act d 1 IgE. Studies of patients with detailed clinical histories repeatedly show that high IgE to Act d 1 clusters with the most serious reactions, including anaphylaxis.

That said, IgE level alone does not perfectly predict how badly you will react. Functional tests like basophil activation (which measures how your immune cells actually respond) can capture risk that a simple antibody level misses. The takeaway: a positive Act d 1 result raises your risk profile and warrants careful management, but it is one input into a larger picture.

Mono-Allergy Versus Cross-Reactive Allergy

If you are allergic to birch pollen and notice itching in your mouth when you eat kiwi, your IgE is most likely targeting Act d 8, not Act d 1. This is called pollen-food syndrome, and the reactions are usually mild and localized. People with isolated kiwi allergy (no pollen connection) more often have IgE to Act d 1, and their reactions tend to be systemic and more severe.

This distinction matters for daily life. A pollen-related kiwi reaction may improve when kiwi is cooked or peeled, because the responsible proteins break down with heat. Reactions driven by Act d 1 do not follow the same rules. The molecule is more stable, and avoidance is the standard recommendation.

How This Test Compares to Standard Kiwi Testing

Standard kiwi allergy testing uses whole-fruit extract, and it misses a lot. Here is how the different approaches stack up in one detailed study.

Source: Bublin et al. 2010, Le et al. 2012.

What this means for you: a negative standard kiwi test does not rule out true allergy. Component testing for Act d 1 catches many of the cases that extract-based tests miss, while also telling you which type of kiwi allergy you have. If you have reacted to kiwi and your standard test came back negative, the Act d 1 component may be where the answer is hiding.

Tracking Your Trend

A single IgE measurement is a snapshot. Allergen-specific IgE levels can shift over months and years, especially in children, who sometimes outgrow food allergies. If you are using this test to monitor a known kiwi allergy, retesting periodically can show whether your sensitization is changing. A baseline test, with follow-up annually or every 1 to 2 years, gives you a trajectory rather than a single data point.

Direct evidence on how Act d 1 IgE specifically changes over time is limited. Across food allergies generally, IgE-mediated sensitization patterns can rise, fall, or persist depending on age, exposure, and underlying biology. Serial testing makes more sense than reading too much into one result, particularly when guiding decisions about continued avoidance or supervised reintroduction.

When Results Can Be Misleading

IgE testing has known interpretive pitfalls. The most important ones to understand:

• Sensitization without symptoms: detectable IgE to Act d 1 does not always mean you will react if you eat kiwi. Some people have positive blood tests but tolerate the fruit. Clinical history matters.
• Cross-reactivity confusion: if you are sensitized to birch pollen or latex, you may show IgE to other kiwi components without having clinical kiwi allergy. The Act d 1 result helps cut through this noise.
• Negative result does not mean safe: some clinically allergic people have low or undetectable Act d 1 IgE, and a negative result does not fully rule out kiwi allergy. Skin testing with fresh fruit or a supervised food challenge may still be needed.
• IgE level does not equal severity: higher Act d 1 IgE is associated with more severe reactions on average, but the relationship is not exact. A modest number does not guarantee a mild reaction.

What to Do With an Unexpected Result

If your Act d 1 IgE comes back positive and you have never reacted to kiwi, do not panic, but do not ignore it either. Pair this result with a careful history of any past kiwi exposure. If you have had reactions, even mild ones, this finding supports working with an allergist to confirm the diagnosis, discuss avoidance, and consider whether you should carry epinephrine. If you have no symptom history, the result represents sensitization that may or may not become clinically meaningful.

Companion tests can sharpen the picture. Running a panel that includes other kiwi components (Act d 2, Act d 8, Act d 9, Act d 10) helps distinguish primary kiwi allergy from pollen-related cross-reaction. A skin prick test, especially using fresh kiwi, adds another layer of confirmation. When the picture is still unclear, a supervised oral food challenge with an allergist remains the most definitive answer. If your result is negative but you have reacted to kiwi, ask about further workup; a single blood marker is not the final word.

How This Test Is Used

There is no established role for screening asymptomatic people with no kiwi exposure history. The test is most useful when you have a reason to wonder: a past reaction, a family history of food allergy, an existing kiwi extract test that did not match your symptoms, or a need to clarify whether your pollen allergy is also driving food reactions. Standard care for confirmed kiwi allergy is avoidance, and there is currently no proven medical treatment that lowers Act d 1 IgE specifically.